Literature DB >> 3346531

Amodiaquine-induced fulminant hepatitis.

J Bernuau1, D Larrey, B Campillo, C Degott, F Verdier, B Rueff, D Pessayre, J P Benhamou.   

Abstract

Three patients suffered from fulminant hepatitis within 23, 59 and 22 weeks after having ingested a total dose of 16, 26 and 15 g, respectively, of amodiaquine for the prophylaxis of malaria. Amodiaquine administration was continued for 44, 21 and 25 days after the onset of jaundice, respectively. One patient underwent emergency orthotopic liver transplantation and survived. The other two died. Fulminant hepatitis threatens patients in whom amodiaquine administration is protracted for several months and not interrupted when jaundice occurs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3346531     DOI: 10.1016/s0168-8278(88)80469-0

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  10 in total

Review 1.  Malaria: prevention in travellers.

Authors:  Ashley M Croft
Journal:  BMJ Clin Evid       Date:  2007-11-29

Review 2.  Malaria: prevention in travellers.

Authors:  Ashley M Croft
Journal:  BMJ Clin Evid       Date:  2010-07-12

Review 3.  Contributions of nonhematopoietic cells and mediators to immune responses: implications for immunotoxicology.

Authors:  Barbara L F Kaplan; Jinze Li; John J LaPres; Stephen B Pruett; Peer W F Karmaus
Journal:  Toxicol Sci       Date:  2015-06       Impact factor: 4.849

4.  Malaria chemoprophylaxis among European tourists in tropical Africa: use, adverse reactions, and efficacy.

Authors:  R Steffen; R Heusser; R Mächler; R Bruppacher; U Naef; D Chen; A M Hofmann; B Somaini
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

Review 5.  Extracts from "Clinical Evidence". Malaria: prevention in travellers.

Authors:  A Croft
Journal:  BMJ       Date:  2000-07-15

6.  Fulminant hepatic failure secondary to hydroxychloroquine.

Authors:  A J Makin; J Wendon; S Fitt; B C Portmann; R Williams
Journal:  Gut       Date:  1994-04       Impact factor: 23.059

7.  Efficacy of intramuscular amopyroquin for treatment of Plasmodium falciparum malaria in the Gabon Republic.

Authors:  C Gaudebout; E Pussard; F Clavier; D Gueret; J Le Bras; O Brandicourt; F Verdier
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

8.  Adverse effects of the antimalaria drug, mefloquine: due to primary liver damage with secondary thyroid involvement?

Authors:  Ashley M Croft; Andrew Herxheimer
Journal:  BMC Public Health       Date:  2002-03-25       Impact factor: 3.295

9.  Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial.

Authors:  Djibrine Djallé; Siméon P Njuimo; Alexandre Manirakiza; Rémi Laganier; Alain Le Faou; Christophe Rogier
Journal:  Malar J       Date:  2014-01-07       Impact factor: 2.979

10.  In Vivo Activity of Repurposed Amodiaquine as a Host-Targeting Therapy for the Treatment of Anthrax.

Authors:  Mikhail Martchenko Shilman; Gloria Bartolo; Saleem Alameh; Johnny W Peterson; William S Lawrence; Jennifer E Peel; Satheesh K Sivasubramani; David W C Beasley; Christopher K Cote; Samandra T Demons; Stephanie A Halasahoris; Lynda L Miller; Christopher P Klimko; Jennifer L Shoe; David P Fetterer; Ryan McComb; Chi-Lee C Ho; Kenneth A Bradley; Stella Hartmann; Luisa W Cheng; Marina Chugunova; Chiu-Yen Kao; Jennifer K Tran; Aram Derbedrossian; Leeor Zilbermintz; Emiene Amali-Adekwu; Anastasia Levitin; Joel West
Journal:  ACS Infect Dis       Date:  2021-07-04       Impact factor: 5.084

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.